[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613377":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":24,"responsibleParty":34,"collaborators":24,"id":36,"slug":24,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":24,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":24,"studyType":48,"phases":49,"briefSummary":39,"conditions":51,"keywords":24,"overallStatus":53,"whyStopped":24,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":24},{"fullName":5,"class":6},"Jetema Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"JTM104","EXPERIMENTAL","HA Filler",[13],"Biological: JTM104",{"label":15,"type":16,"description":11,"interventionNames":17},"Juvederm® ULTRA PLUS XC","ACTIVE_COMPARATOR",[18],"Biological: Juvederm® ULTRA PLUS XC",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","JTM104 contains 22.8 mg\u002FmL cross-linked hyaluronic acid, 1.2 mg\u002FmL hyaluronic acid, and 3 mg\u002FmL lidocaine. The product will be injected into the nasolabial folds, with a maximum volume of 1 mL per side.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Juvederm® ULTRA PLUS XC contains 22.8 mg\u002FmL cross-linked hyaluronic acid, 1.2 mg\u002FmL hyaluronic acid, and 3 mg\u002FmL lidocaine. The product will be injected into the nasolabial folds, with a maximum volume of 1 mL per side.",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Jetema_clinical","CONTACT","+820317889520","joohee@jetema.com",{"type":35,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100613377",false,"NCT07265791","Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds","Multicenter, Randomized, Subject & Independent Evaluator-blind, Matched Pairs, Active-controlled, Non-inferiority, Pivotal Study to Evaluate the Efficacy and Safety of Injection With JTM104 as Compared to Juvederm® ULTRA PLUS XC in Temporary Correction of Moderate to Severe Nasolabial Folds","Inclusion Criteria:\n\n* Adults aged 19 to 75 years\n* Voluntarily provided written informed consent\n* Moderate to severe symmetrical nasolabial folds (WSRS score 3 or 4 on both sides)\n* Agree to discontinue other facial dermatologic treatments (e.g., fillers, botulinum toxin, laser) during the study\n* Able to understand instructions and comply with study procedures\n\nExclusion Criteria:\n\n* Untreated scars or facial skin infections\u002Fdiseases affecting the mid\u002Flower face within the past year\n* History of severe allergy or hypersensitivity to device components\n* Facial invasive procedures within the past 6 months (including surgery, laser, botulinum toxin)\n* Use of certain medications (anticoagulants, immunosuppressants, steroids) within specified washout periods\n* Participation in other interventional clinical trials within 4 weeks before screening or during study\n* Non-compliance with contraception requirements or pregnancy\u002Flactation during study\n* Deemed unsuitable by investigator for any other reason","ALL","19 Years","75 Years",{"count":46,"type":47},100,"ESTIMATED","INTERVENTIONAL",[50],"NA",[52],"Nasolabial Folds, Wrinkles","NOT_YET_RECRUITING","2025-11-24",{"date":56,"type":57},"2025-12-05","ACTUAL",{"date":59,"type":47},"2026-01-03",{"date":61,"type":47},"2027-01-31",{"name":5,"class":6}]